Mandate

Vinge advises Cell Impact in connection with its fully guaranteed rights issue of SEK 349 million

December 01, 2021 Capital Markets and Public M&A

Vinge advises Cell Impact AB (publ) in connection with a fully guaranteed rights issue which will provide Cell Impact with gross issue proceeds of SEK 349 million

Cell Impact is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique scalable method for high-velocity forming, Cell Impact Forming™, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.

Vinge’s team consisted of Johan Larsson, Dain Hård Nevonen, Anna Jonsson, Rikard Lindahl, Joel Magnusson and Lorin Arabi.

 

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024